Showing 1–2 of 2 results for author: Iorio, F
-
A subtractive manufacturing constraint for level set topology optimization
Authors:
Nigel Morris,
Adrian Butscher,
Francesco Iorio
Abstract:
We present a method for enforcing manufacturability constraints in generated parts such that they will be automatically ready for fabrication using a subtractive approach. We primarily target multi-axis CNC milling approaches but the method should generalize to other subtractive methods as well. To this end, we take as user input: the radius of curvature of the tool bit, a coarse model of the tool…
▽ More
We present a method for enforcing manufacturability constraints in generated parts such that they will be automatically ready for fabrication using a subtractive approach. We primarily target multi-axis CNC milling approaches but the method should generalize to other subtractive methods as well. To this end, we take as user input: the radius of curvature of the tool bit, a coarse model of the tool head and optionally a set of milling directions. This allows us to enforce the following manufacturability conditions: 1) surface smoothness such that the radius of curvature of the part does not exceed the milling bit radius, 2) orientation such that every part of the surface to be milled is visible from at least one milling direction, 3) accessibility such that every surface patch can be reached by the tool bit without interference with the tool or head mount. We will show how to efficiently enforce the constraint during level set-based topology optimization modifying the advection velocity such that at each iteration the topology optimization maintains a descent optimization direction and does not violate any of the manufacturability conditions. This approach models the actual subtractive process by carving away material accessible to the machine at each iteration until a local optimum is achieved.
△ Less
Submitted 19 February, 2020;
originally announced February 2020.
-
Machine learning prediction of cancer cell sensitivity to drugs based on genomic and chemical properties
Authors:
Michael P. Menden,
Francesco Iorio,
Mathew Garnett,
Ultan McDermott,
Cyril Benes,
Pedro J. Ballester,
Julio Saez-Rodriguez
Abstract:
Predicting the response of a specific cancer to a therapy is a major goal in modern oncology that should ultimately lead to a personalised treatment. High-throughput screenings of potentially active compounds against a panel of genomically heterogeneous cancer cell lines have unveiled multiple relationships between genomic alterations and drug responses. Various computational approaches have been…
▽ More
Predicting the response of a specific cancer to a therapy is a major goal in modern oncology that should ultimately lead to a personalised treatment. High-throughput screenings of potentially active compounds against a panel of genomically heterogeneous cancer cell lines have unveiled multiple relationships between genomic alterations and drug responses. Various computational approaches have been proposed to predict sensitivity based on genomic features, while others have used the chemical properties of the drugs to ascertain their effect. In an effort to integrate these complementary approaches, we developed machine learning models to predict the response of cancer cell lines to drug treatment, quantified through IC50 values, based on both the genomic features of the cell lines and the chemical properties of the considered drugs. Models predicted IC50 values in a 8-fold cross-validation and an independent blind test with coefficient of determination R2 of 0.72 and 0.64 respectively. Furthermore, models were able to predict with comparable accuracy (R2 of 0.61) IC50s of cell lines from a tissue not used in the training stage. Our in silico models can be used to optimise the experimental design of drug-cell screenings by estimating a large proportion of missing IC50 values rather than experimentally measure them. The implications of our results go beyond virtual drug screening design: potentially thousands of drugs could be probed in silico to systematically test their potential efficacy as anti-tumour agents based on their structure, thus providing a computational framework to identify new drug repositioning opportunities as well as ultimately be useful for personalized medicine by linking the genomic traits of patients to drug sensitivity.
△ Less
Submitted 18 March, 2013; v1 submitted 3 December, 2012;
originally announced December 2012.
